Overview

A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Status:
Completed

Trial end date:
2008-05-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this trial is to estimate the drug effect on tumors in patients with ovarian or primary peritoneal cancers. Patients will receive Pemetrexed every 21 days until disease progression or unacceptable toxicity. This medication will be given over 10 minutes and may be administered intravenously (IV), through a vein in your arm. Vitamin supplementation is a required part of this study.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Gynecologic Oncology Group

Treatments:

Pemetrexed